deferoxamine has been researched along with Adenocarcinoma in 19 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Adenocarcinoma: A malignant epithelial tumor with a glandular organization.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Therefore, this study aimed to clarify the role of PYCR1 and its interaction with SLC25A10 in a chemotherapeutic agent 5-fluorouracil (5-FU)'s toxicity to colorectal cancer cells." | 8.12 | The role of PYCR1 in inhibiting 5-fluorouracil-induced ferroptosis and apoptosis through SLC25A10 in colorectal cancer. ( Mai, Z; Qiu, X; Song, Y; Xia, W; Yang, X; Ye, Y; Zhang, M; Zhou, B, 2022) |
| " Therefore, this study aimed to clarify the role of PYCR1 and its interaction with SLC25A10 in a chemotherapeutic agent 5-fluorouracil (5-FU)'s toxicity to colorectal cancer cells." | 4.12 | The role of PYCR1 in inhibiting 5-fluorouracil-induced ferroptosis and apoptosis through SLC25A10 in colorectal cancer. ( Mai, Z; Qiu, X; Song, Y; Xia, W; Yang, X; Ye, Y; Zhang, M; Zhou, B, 2022) |
| "Effect of the iron chelator deferoxamine (DF) on the production of endogenous porphyrins was studied in adenocarcinoma WiDr cells and erythroid K562 cells in vitro." | 3.73 | Deferoxamine photosensitizes cancer cells in vitro. ( Juzenas, P; Juzeniene, A; Moan, J, 2005) |
| "This study reports the stability of mRNA of type-1 plasminogen activator inhibitor (PAI-1), the major physiologic inhibitor of plasminogen activation, by deferoxamine-aided iron deprivation, in PC3 adenocarcinoma cells." | 3.73 | Iron-mediated stability of PAI-1 mRNA in adenocarcinoma cells-involvement of a mRNA-binding nuclear protein. ( Harish Kumar, M; Maruyama, M; Omura, S; Radha, KS; Sugiki, M; Yoshida, E, 2005) |
| "In conclusion, breast cancer cells up-regulate the expression of iron importer genes and down-regulate the expression of iron exporter SLC40A1 to satisfy their increased demand for iron." | 1.36 | Manipulation of iron transporter genes results in the suppression of human and mouse mammary adenocarcinomas. ( Elliott, RL; Head, JF; Jiang, XP, 2010) |
| "Idiopathic hemochromatosis is frequently associated with various malignancies including hepatic carcinoma." | 1.28 | [A case of idiopathic hemochromatosis associated with gastric cancer]. ( Akagi, K; Fujishima, M; Ishitsuka, T; Nomiyama, K; Okamura, T; Shibuya, T; Sugie, Y; Tsuji, H, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (36.84) | 18.2507 |
| 2000's | 8 (42.11) | 29.6817 |
| 2010's | 3 (15.79) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Zhou, B | 1 |
| Mai, Z | 1 |
| Ye, Y | 1 |
| Song, Y | 1 |
| Zhang, M | 1 |
| Yang, X | 1 |
| Xia, W | 1 |
| Qiu, X | 1 |
| Salis, O | 1 |
| Bedir, A | 1 |
| Kilinc, V | 1 |
| Alacam, H | 1 |
| Gulten, S | 1 |
| Okuyucu, A | 1 |
| Lakhal, S | 1 |
| Talbot, NP | 1 |
| Crosby, A | 1 |
| Stoepker, C | 1 |
| Townsend, AR | 1 |
| Robbins, PA | 1 |
| Pugh, CW | 1 |
| Ratcliffe, PJ | 1 |
| Mole, DR | 1 |
| Klenow, S | 1 |
| Glei, M | 1 |
| Jiang, XP | 1 |
| Elliott, RL | 1 |
| Head, JF | 1 |
| Ruggiero, A | 1 |
| Villa, CH | 1 |
| Holland, JP | 1 |
| Sprinkle, SR | 1 |
| May, C | 1 |
| Lewis, JS | 1 |
| Scheinberg, DA | 1 |
| McDevitt, MR | 1 |
| Watts, RN | 1 |
| Richardson, DR | 1 |
| Chong, TW | 1 |
| Horwitz, LD | 1 |
| Moore, JW | 1 |
| Sowter, HM | 1 |
| Harris, AL | 1 |
| Juzenas, P | 1 |
| Juzeniene, A | 1 |
| Moan, J | 1 |
| Radha, KS | 1 |
| Sugiki, M | 1 |
| Yoshida, E | 1 |
| Harish Kumar, M | 1 |
| Omura, S | 1 |
| Maruyama, M | 1 |
| Alvarez, MG | 1 |
| Lacelli, MS | 1 |
| Rivarola, V | 1 |
| Batlle, A | 1 |
| Fukuda, H | 1 |
| Lindnér, P | 1 |
| Naredi, P | 1 |
| Peterson, A | 1 |
| Hafström, L | 1 |
| Nguyen, TD | 1 |
| Canada, AT | 1 |
| Nakajima, M | 1 |
| Shinoda, I | 1 |
| Samejima, Y | 1 |
| Miyauchi, H | 1 |
| Fukuwatari, Y | 1 |
| Hayasawa, H | 1 |
| Dreicer, R | 1 |
| Kemp, JD | 1 |
| Stegink, LD | 1 |
| Cardillo, T | 1 |
| Davis, CS | 1 |
| Forest, PK | 1 |
| See, WA | 1 |
| Parkins, CS | 1 |
| Holder, AL | 1 |
| Dennis, MF | 1 |
| Stratford, MR | 1 |
| Chaplin, DJ | 1 |
| Jiménez, LA | 1 |
| Thompson, J | 1 |
| Brown, DA | 1 |
| Rahman, I | 1 |
| Antonicelli, F | 1 |
| Duffin, R | 1 |
| Drost, EM | 1 |
| Hay, RT | 1 |
| Donaldson, K | 1 |
| MacNee, W | 1 |
| Sugie, Y | 1 |
| Tsuji, H | 1 |
| Nomiyama, K | 1 |
| Ishitsuka, T | 1 |
| Akagi, K | 1 |
| Fujishima, M | 1 |
| Shibuya, T | 1 |
| Okamura, T | 1 |
| Holmes, KT | 1 |
| Lean, CL | 1 |
| Hunt, NH | 1 |
| King, NJ | 1 |
2 trials available for deferoxamine and Adenocarcinoma
| Article | Year |
|---|---|
Regulation of growth differentiation factor 15 expression by intracellular iron.
Topics: Adenocarcinoma; Anemia, Iron-Deficiency; Basic Helix-Loop-Helix Transcription Factors; Breast Neopla | 2009 |
A phase II trial of deferoxamine in patients with hormone-refractory metastatic prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Creatinine; Deferoxami | 1997 |
17 other studies available for deferoxamine and Adenocarcinoma
| Article | Year |
|---|---|
The role of PYCR1 in inhibiting 5-fluorouracil-induced ferroptosis and apoptosis through SLC25A10 in colorectal cancer.
Topics: Adenocarcinoma; Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Colorectal Neoplasms; Deferoxamine; | 2022 |
The anticancer effects of desferrioxamine on human breast adenocarcinoma and hepatocellular carcinoma cells.
Topics: Adenocarcinoma; Breast Neoplasms; Carcinoma, Hepatocellular; Cell Cycle Proteins; Deferoxamine; Fema | 2014 |
New insight into the influence of carob extract and gallic acid on hemin induced modulation of HT29 cell growth parameters.
Topics: Adenocarcinoma; Adult; Antioxidants; Cell Proliferation; Colonic Neoplasms; Deferoxamine; Dose-Respo | 2009 |
Manipulation of iron transporter genes results in the suppression of human and mouse mammary adenocarcinomas.
Topics: Adenocarcinoma; Animals; Breast Neoplasms; Cation Transport Proteins; Cell Line, Tumor; Chlorides; D | 2010 |
Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes.
Topics: Actinium; Adenocarcinoma; Animals; Cell Line, Tumor; Colonic Neoplasms; Deferoxamine; Heterocyclic C | 2010 |
The mechanism of nitrogen monoxide (NO)-mediated iron mobilization from cells. NO intercepts iron before incorporation into ferritin and indirectly mobilizes iron from ferritin in a glutathione-dependent manner.
Topics: Adenocarcinoma; Animals; Breast Neoplasms; Cell Membrane Permeability; Cell-Free System; Cytosol; De | 2002 |
A mycobacterial iron chelator, desferri-exochelin, induces hypoxia-inducible factors 1 and 2, NIP3, and vascular endothelial growth factor in cancer cell lines.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Basic Helix-Loop-Helix Transcription Factors; Brea | 2002 |
Deferoxamine photosensitizes cancer cells in vitro.
Topics: Adenocarcinoma; Cell Line, Tumor; Cell Survival; Deferoxamine; Dose-Response Relationship, Drug; Dos | 2005 |
Iron-mediated stability of PAI-1 mRNA in adenocarcinoma cells-involvement of a mRNA-binding nuclear protein.
Topics: 3' Untranslated Regions; Adenocarcinoma; Cell Line, Tumor; Deferoxamine; Ferric Compounds; Humans; I | 2005 |
5-aminolevulinic acid-mediated photodynamic therapy on Hep-2 and MCF-7c3 cells.
Topics: Adenocarcinoma; Aminolevulinic Acid; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Survival; D | 2007 |
Influence of hepatic artery occlusion and desferrioxamine on liver-tumour growth.
Topics: Adenocarcinoma; Alanine Transaminase; Animals; Aspartate Aminotransferases; Body Weight; Cell Divisi | 1995 |
Modulation of human colonic T84 cell secretion by hydrogen peroxide.
Topics: Adenocarcinoma; Carbachol; Catalase; Chlorides; Colonic Neoplasms; Deferoxamine; Dithiothreitol; Ele | 1994 |
Lactoferrin as a suppressor of cell migration of gastrointestinal cell lines.
Topics: Adenocarcinoma; Animals; Apoproteins; Cattle; Cell Movement; Colonic Neoplasms; Deferoxamine; Digest | 1997 |
Involvement of oxygen free radicals in ischaemia-reperfusion injury to murine tumours: role of nitric oxide.
Topics: Adenocarcinoma; Animals; Catalase; Deferoxamine; Endothelium, Vascular; Female; Free Radical Scaveng | 1998 |
Activation of NF-kappaB by PM(10) occurs via an iron-mediated mechanism in the absence of IkappaB degradation.
Topics: Adenocarcinoma; Air Pollutants; Cell Nucleus; Deferoxamine; DNA; DNA-Binding Proteins; Drug Interact | 2000 |
[A case of idiopathic hemochromatosis associated with gastric cancer].
Topics: Adenocarcinoma; Aged; Deferoxamine; Fibrosis; Hemochromatosis; Humans; Liver; Male; Stomach Neoplasm | 1992 |
Development of the "activated" high resolution 1H MR spectrum in murine T cells and B cells occurs in G1 phase of the cell cycle.
Topics: Adenocarcinoma; Animals; B-Lymphocytes; Cells, Cultured; Deferoxamine; G1 Phase; Hydroxyurea; Lympho | 1990 |